Sold as Mentax, Lotrimin Ultra, Mentax-Tc. Every FDA application for this active ingredient: 4 branded and 1 generic.
As of Nov 16, 2026, FDA lists 5 applications for Butenafine Hydrochloride (sold as Mentax, Lotrimin Ultra, Mentax-Tc), first approved Oct 18, 1996, with 3 new uses approved and 0 published complete response letters.
| Oct 18, 1996 | MentaxNDA 20524 · New molecular entity | Pharmobedient | 6 | Discontinued |
| Dec 31, 1996 | MentaxNDA 20663 · TYPE 6 | Mylan Bertek | 0 | Marketed |
| Dec 7, 2001 | Lotrimin UltraNDA 21307 · TYPE 8 | Bayer Healthcare LLC | 12 | Marketed |
| Oct 17, 2002 | Mentax-TcNDA 21408 · New dosage form | Pharmobedient | 0 | Discontinued |
| Nov 16, 2017 | Butenafine HydrochlorideANDA 205181 | Sun Pharma Canada | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA